Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines (original) (raw)

2011, Journal of the American College of Cardiology

AI-generated Abstract

This meta-analysis investigated the efficacy and safety of glycoprotein IIb/IIIa inhibitors (GPIs) during elective coronary revascularization, specifically in the context of stents and thienopyridines. The analysis included randomized trials that reported clinical outcomes within 30 days post-procedure. Findings indicated that GPIs significantly reduced the incidence of nonfatal myocardial infarction compared to control, with a relative risk of 0.66. However, the rates of major bleeding were comparable between groups, suggesting that while GPIs improve certain outcomes, they do not significantly increase bleeding risks.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact